| Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund |
2020-07-03 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Calliditas Therapeutics–SEVERAL: investment, 202005– filing of US IPO of ADSs at Nasdaq Global Market |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005– private placement outside US announced concurrent filing of US IPO of ADSs |
2020-05-14 |
| Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share |
2020-05-05 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| Leo Pharma–Oneness Biotech: therapeutic antibody, 202004– license ww excl to FB825 $40m upfront + $530m milestones + royalties from Oneness + MBS |
2020-04-15 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Servier: investment, 202004–202006 acquisition 100% €na |
2020-04-03 |
| Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments |
2020-03-31 |
| Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche |
2020-03-31 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
| Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price |
2020-03-13 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Genmab–Genedata: bioinformatics, 202002 supply existent Genmab is existing customer of Genedata |
2020-02-26 |
| InstruNor–Fluidigm: investment, 202002 acquisition $7.2m with $5.2m in cash + $2m in stock |
2020-02-26 |
| Lundbeck–Genedata: bioinformatics, 202002 supply existent Lundbeck is existing customer of Genedata |
2020-02-26 |
| Merus–Genedata: bioinformatics, 202002 supply existent Merus is existing customer of Genedata |
2020-02-26 |
| Novo Group–Genedata: bioinformatics, 202002 supply existent Novo Nordisk is existing customer of Genedata |
2020-02-26 |
| Novo Group–Genedata: bioinformatics, 202002 supply existent Novozymes is existing customer of Genedata |
2020-02-26 |
| FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m |
2020-02-21 |
| Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares |
2020-02-07 |
| Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies |
2020-01-28 |
| Blueprint Genetics–Quest Diagnostics: investment, 202001 acquisition €na by Quest Diagnostics |
2020-01-22 |
| HepaRegenix–Novo Group: investment, 202001 financing round Series B totalling €11m incl existing investor Novo Seeds |
2020-01-21 |
| HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion |
2020-01-21 |
| Nanoform–Coulter Partners: recruitment services, 202001 supply service placement of Sally Langa as new head of US Sales at Nanoform |
2020-01-21 |
| Biograil–High-Tech Gründerfonds: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl lead investor HTGF |
2020-01-15 |
| Biograil–Megatrend Invest: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Megatrend Invest A/S |
2020-01-15 |
| Biograil–OTHER: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl a Danish private healthcare investor |
2020-01-15 |
| Biograil–SEVERAL: investment, 202001 seed financing round €3m (potentially up to €5m) led by HTGF |
2020-01-15 |
| Biograil–Swiss Investment Group: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl co-investor Swiss Investment Group |
2020-01-15 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund |
2020-01-06 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures |
2019-12-18 |
| BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications |
2019-12-06 |
| Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services |
2019-12-06 |
| Elypta–Chalmers Univ: investment, 201912 late seed financing round totalling €6.1m incl existing + co-investor Chalmers Ventures |
2019-12-01 |
| Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |
| Elypta–Norrsken Foundation: investment, 201912 late seed financing round totalling €6.1m incl co-investor Norrsken VC |
2019-12-01 |
| Elypta–Sciety: investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Sciety |
2019-12-01 |
| Elypta–SEVERAL: investment, 201912 late seed financing round €6.1m co-led by Industrifonden + Sciety |
2019-12-01 |
| Elypta–Sweden (govt): investment, 201912 late seed financing round totalling €6.1m incl co-lead investor Industrifonden |
2019-12-01 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum |
2019-11-26 |
| Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec |
2019-11-25 |
| Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S |
2019-11-25 |
| Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies |
2019-11-19 |
| Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with r+d collab |
2019-11-18 |
| Novo Group–Dicerna Pharmaceuticals: RNAi therapeutics, 201911– collab r+d $175m upfront + milestones + investm RNAi drugs liver diseases using GalXC |
2019-11-18 |
| Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc |
2019-10-31 |
| Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie |
2019-10-29 |
| Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S |
2019-10-29 |
| Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S |
2019-10-29 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m |
2019-10-22 |
| Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN |
2019-10-21 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit |
2019-10-16 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
